| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Four attenuated strains of type 1 dengue virus were selected by serial passage into suckling or weanling mice through inoculation by either the intraspinal or intracerebral routes. The strains so selected differed slightly from one another in their capacity to multiply in the brains of weanling mice but all proliferated readily in suckling mouse nervous tissue. None produced neurological signs or histological lesions of consequence in intracerebrally inoculated rhesus monkeys.
Three of the strains produced a recognizable, but highly modified, infection in man, including the development of a mild rash which was consistent on clinical grounds with a very diminutive dengue fever. One strain, the MD-1 strain derived by serial passage in suckling mouse brain, produced an inapparent infection in human subjects, even when as many as 200,000 suckling mouse intracerebral LD50 doses were given. All four strains, including the MD-1 strain, elicited the production of type 1 dengue neutralizing antibodies which began to appear in the second week after vaccination and attained a maximum titer between three and four weeks after vaccination. The MD-1 strain is undergoing further study and evaluation as a potential attenuated living vaccine for the prevention of type 1 dengue fever.
This work was carried out under the aegis of the Commission on Immunization of the Armed Forces Epidemiological Board and was largely supported by Contract DA-49-007-MD-660 with the Research and Development Command, Office of the Surgeon General, Department of the Army.
* Presented at Symposium on Immunization Against Arthropod-borne Virus Infections, held Nov. 2, 1962 during the Atlanta meeting of the American Society of Tropical Medicine and Hygiene.
Present address: Merck Institute for Research, West Point, Pennsylvania.
This article has been cited by other articles:
|
|
 |
|
  B. L. INNIS and K. H. ECKELS PROGRESS IN DEVELOPMENT OF A LIVE-ATTENUATED, TETRAVALENT DENGUE VIRUS VACCINE BY THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND Am J Trop Med Hyg, December 1, 2003; 69(90060): 1 - 4. [Full Text] [PDF]
|
|
|
|
|
|
K. H. ECKELS, D. R. DUBOIS, R. PUTNAK, D. W. VAUGHN, B. L. INNIS, E. A. HENCHAL, and C. H. HOKE JR. MODIFICATION OF DENGUE VIRUS STRAINS BY PASSAGE IN PRIMARY DOG KIDNEY CELLS: PREPARATION OF CANDIDATE VACCINES AND IMMUNIZATION OF MONKEYS Am J Trop Med Hyg, December 1, 2003; 69(90060): 12 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Guirakhoo, R. Weltzin, T. J. Chambers, Z.-X. Zhang, K. Soike, M. Ratterree, J. Arroyo, K. Georgakopoulos, J. Catalan, and T. P. Monath Recombinant Chimeric Yellow Fever-Dengue Type 2 Virus Is Immunogenic and Protective in Nonhuman Primates J. Virol., June 15, 2000; 74(12): 5477 - 5485. [Abstract] [Full Text]
|
|
|
|
|
|
Y.-L. Lin, C.-L. Liao, L.-K. Chen, C.-T. Yeh, C.-I Liu, S.-H. Ma, Y.-Y. Huang, Y.-L. Huang, C.-L. Kao, and C.-C. King Study of Dengue Virus Infection in SCID Mice Engrafted with Human K562 Cells J. Virol., December 1, 1998; 72(12): 9729 - 9737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Gubler Dengue and Dengue Hemorrhagic Fever Clin. Microbiol. Rev., July 1, 1998; 11(3): 480 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bray, R. Men, I. Tokimatsu, and C.-J. Lai Genetic Determinants Responsible for Acquisition of Dengue Type 2 Virus Mouse Neurovirulence J. Virol., February 1, 1998; 72(2): 1647 - 1651. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
